表紙
市場調査レポート

世界の糖尿病性神経障害市場

Global Diabetic Neuropathy Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 302347
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
世界の糖尿病性神経障害市場 Global Diabetic Neuropathy Market 2014-2018
出版日: 2014年05月09日 ページ情報: 英文 55 Pages
概要

世界の糖尿病性神経障害(DN)市場は、2014年〜2018年のCAGRで、8.41%の成長が見込まれています。

当レポートでは、世界の糖尿病性神経障害(DN)市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会などを検証するほか、主要ベンダープロファイルも含めて、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 地域区分

第8章 購買基準

第9章 市場成長促進要因

第10章 促進要因とその影響

第11章 市場課題

第12章 促進要因と課題の影響

第13章 市場動向

第14章 動向とその影響

第15章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第16章 主要ベンダー分析

  • 事業概要、事業区分、主要情報、SWOT分析
    • Pfizer Inc.
    • Eli Lilly and Company
    • Janssen Pharmaceuticals Inc.

第17章 パイプライン分析

第18章 関連レポート

図表

目次
Product Code: IRTNTR3501

About Diabetic Neuropathy

Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.

TechNavio's analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Diabetic Neuropathy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various pain management drugs administered to relieve the pain symptoms associated with diabetic neuropathy. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Diabetic Neuropathy market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Diabetic Neuropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Neuropathy market landscape and its growth prospects in the coming years.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Eli Lilly and Co.
  • Janssen Pharmaceuticals Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • Actavis plc
  • Cephalon Inc.
  • MEDA Pharma GmbH & Co. KG

Key Market Driver

  • Increasing Global Diabetic Population.

For a full, detailed list, view our report.

Key Market Challenge

  • High Failure Rate in Clinical Trials.

For a full, detailed list, view our report.

Key Market Trend

  • Increasing R&D Activities.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Geographical Segmentation

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape

  • 15.1. Competitive Scenario
    • 15.1.1. Key News
    • 15.1.2. Mergers and Acquisitions
  • 15.2. Market Share Analysis 2013
  • 15.3. Other Prominent Vendors

16. Key Vendor Analysis

  • 16.1. Pfizer Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Key Information
    • 16.1.3. SWOT Analysis
  • 16.2. Eli Lilly and Company
    • 16.2.1. Business Overview
    • 16.2.2. Business Segmentation
    • 16.2.3. Key Information
    • 16.2.4. SWOT Analysis
  • 16.3. Janssen Pharmaceuticals Inc.
    • 16.3.1. Business Overview
    • 16.3.2. Key Information
    • 16.3.3. SWOT Analysis
    • 17. Pipeline Analysis
  • 17.1. Phase III Analysis
  • 17.2. Phase II Analysis
  • 17.3. Phase I Analysis
  • 17.4. Discontinued Projects
  • 17.5. Projects on Hold
  • 17.6. Promising Pipeline Molecules
    • 17.6.1. Phase III Promising Pipeline Molecules
    • 17.6.2. Phase II Promising Pipeline Molecules
  • 17.7. Other First-in-class Pipeline Molecules:

18. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Diabetic Neuropathy Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Diabetic Neuropathy Market by Geographical Segmentation 2013
  • Exhibit 4: Eli Lilly and Company: Business Segmentation
  • Exhibit 5: Diabetic Neuropathy Pipeline Snapshot 2013
  • Exhibit 6: Discontinued Pipeline Molecules on the basis of MOA
Back to Top